Monteris Medical Announces $73 Million in Combined Equity and Debt Financing

InnovaHealth Partners leads financing with Birchview Capital and Madryn Asset Management, LP, to accelerate commercial, clinical and product development priorities

Monteris Medical, a private medical technology company dedicated to becoming the technology leader in minimally invasive brain surgery, announced it has secured $73 million in financing including $35 million in new Series D equity and a $38 million debt facility. The equity financing was led by new investor, InnovaHealth Partners, and was supported by existing lead investor, Birchview Capital.

The debt facility, provided by Madryn Asset Management, LP, extended $28 million at closing, with the option to draw an additional $10 million upon the achievement of certain milestones. The proceeds will be used to support important market adoption, clinical research and technology programs and will permit the company to refinance its current obligation.

“Brain tumor and drug-resistant epilepsy patients and their physicians are looking for less invasive options when making their treatment decisions,” said Martin J. Emerson, Monteris Medical’s president and chief executive officer. “NeuroBlate has been proven to offer a less invasive option for patients considering open brain surgery and is also a valuable minimally invasive tool to address surgical locations in the brain that are not accessible with more invasive traditional methods. The Monteris Medical team is pleased to add InnovaHealth and Madryn as financial partners, allowing us to further expand our efforts to bring the value of the NeuroBlate technology to more physicians and the patients we collectively serve.”

The proceeds of this financing will be used to continue to support the rapid adoption of Monteris Medical’s NeuroBlate® System, an MR-guided laser ablation system that allows for a minimally invasive surgical alternative to open craniotomies. The NeuroBlate System is currently installed in more than 100 hospitals in the United States and Canada and is actively used in minimally invasive treatment approaches for patients with drug-resistant epilepsy, primary and metastatic brain tumors, and radiation necrosis. These proceeds will also be used to continue ongoing clinical research, including exciting work in adjuvant immunotherapies, and technology advancement projects for the NeuroBlate System.

“Monteris Medical’s NeuroBlate technology and the company’s increasing depth of clinical evidence are transforming how physicians and their patients think about brain surgery. We are proud to support the expansion of this important technology,” said Mortimer “Tim” Berkowitz III, InnovaHealth’s president and chief executive officer.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy